Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

Ichikawa, Junya; Yoshida, Tatsuya; Isser, Ariel; Laino, Andressa S.; Vassallo, Melinda; Woods, David M.; Kim, Sojung; Oelke, Mathias; Jones, Kristi; Schneck, Jonathan P.; Weber, Jeffrey S.

doi:10.1158/1078-0432.ccr-19-3487

Cited by 28 publications

(26 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noteworthy is that starting leukapheresis material contains a large population of naïve T cells on day 0 (∼21%), while the final product contains on average less than 3% naïve T cells, as shown in Figure 4A. Furthermore, as demonstrated by Ichikawa et al [18], similar memory cell populations and subtypes are also produced from relapsed refractory melanoma patients when compared to healthy donors. Thus, this AIM-np-based approach reproducibly manufactures T-cell products that have the desired combination of memory phenotypes that have the potential to mediate an effective and long-lasting anti-tumor response.…”

Section: In Vitro Characterization Of Aim-expanded T-cell Productsmentioning

confidence: 83%

“…3B). In a separate study comparing specificity, phenotype, and functionality of T-cell products, Ichikawa et al [18] have shown that the AIM-np based E+E process generates Mart-1-specific T-cell products from both healthy donors and melanoma patients that are far superior to T-cell products that were generated with peptide-loaded autologous DCs. As antigen-specific T cells are enriched from the endogenous T-cell repertoire, donor-to-donor variability will affect final composition of the product.…”

Section: Antigen Specificity Of Aim-expanded T-cell Productsmentioning

confidence: 99%

See 1 more Smart Citation

AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties

Suarez

Wang

Carmer

et al. 2020

Transfus Med Hemother

Self Cite

View full text Add to dashboard Cite

Over the last decade, tremendous progress has been made in the field of adoptive cell therapy. The two prevailing modalities include endogenous non-engineered approaches and genetically engineered T-cell approaches. Endogenous non-engineered approaches include dendritic cell-based systems and tumor-infiltrating lymphocytes (TIL) that are used to produce multi-antigen-specific T-cell products. Genetically engineered approaches, such as T-cell receptor engineered cells and chimeric antigen receptor T cells are used to produce single antigen-specific T-cell products. It is noted by the authors that there are alternative methods to sort for antigen-specific T cells such as peptide multimer sorting or cytokine secretion assay-based sorting, both of which are potentially challenging for broad development and commercialization. In this review, we are focusing on a novel nanoparticle technology that generates a non-engineered product from the endogenous T-cell repertoire. The most common approaches for ex vivo activation and expansion of endogenous, non-genetically engineered cell therapy products rely on dendritic cell-based systems or IL-2 expanded TIL. Hurdles remain in developing efficient, consistent, controlled processes; thus, these processes still have limited access to broad patient populations. Here, we describe a novel approach to produce cellular therapies at clinical scale, using proprietary nanoparticles combined with a proprietary manufacturing process to enrich and expand antigen-specific CD8<sup>+</sup> T-cell products with consistent purity, identity, and composition required for effective and durable anti-tumor response.

show abstract

Section: In Vitro Characterization Of Aim-expanded T-cell Productsmentioning

confidence: 83%

Section: Antigen Specificity Of Aim-expanded T-cell Productsmentioning

confidence: 99%

AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties

Suarez

Wang

Carmer

et al. 2020

Transfus Med Hemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…The efficacy of aAPCs could be improved by modifying the nanoparticle morphology 182 , signal coupling 183 , and fluidity 136 . Further exploration and establishment of protocols of aAPCs with personalized neoantigens may generate highly effective and personalized tumor vaccines 184 , 185 . In a recent study, the immune response of autologous tumor antigen was enhanced by a hybrid membrane delivery strategy 77 .…”

Section: Nanovaccines For Diseases Prevention and Treatmentsmentioning

confidence: 99%

Emerging vaccine nanotechnology: From defense against infection to sniping cancer

Feng

Ferdows

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Looking retrospectively at the development of humanity, vaccination is an unprecedented medical landmark that saves lives by harnessing the human immune system. During the ongoing coronavirus disease 2019 (COVID-19) pandemic, vaccination is still the most effective defense modality. The successful clinical application of the lipid nanoparticle-based Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines highlights promising future of nanotechnology in vaccine development. Compared with conventional vaccines, nanovaccines are supposed to have advantages in lymph node accumulation, antigen assembly, and antigen presentation; they also have, unique pathogen biomimicry properties because of well-organized combination of multiple immune factors. Beyond infectious diseases, vaccine nanotechnology also exhibits considerable potential for cancer treatment. The ultimate goal of cancer vaccines is to fully mobilize the potency of the immune system as a living therapeutic to recognize tumor antigens and eliminate tumor cells, and nanotechnologies have the requisite properties to realize this goal. In this review, we summarize the recent advances in vaccine nanotechnology from infectious disease prevention to cancer immunotherapy and highlight the different types of materials, mechanisms, administration methods, as well as future perspectives.

show abstract

“…Micro- and nanomaterial-based artificial APCs (aAPCs) are designed to mimic the natural APCs by presenting important signal antigens to T cells and activate them for cancer inhibition. 136 , 137 To realize these antigen-presenting effects, aAPCs should include two parts on their surface: MHC-peptide complexes that can present cognate antigenic peptide to T cell receptors and co-stimulatory molecules that can bind to co-stimulatory receptors and activate T cells. Compared with natural DCs, aAPCs have a relatively defined composition and controllable biological behavior.…”

Section: Harnessing Peripheral Immune Cellsmentioning

confidence: 99%

Nanotechnology-enhanced immunotherapy for metastatic cancer

Zhang

Meng

et al. 2021

The Innovation

View full text Add to dashboard Cite

A vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective treatments for metastases are currently lacking due to the difficulty of selectively targeting these small, delocalized tumors distributed across a variety of organs. However, nanotechnology holds tremendous promise for improving immunotherapeutic outcomes in patients with metastatic cancer. In contrast to conventional cancer immunotherapies, rationally designed nanomaterials can trigger specific tumoricidal effects, thereby improving immune cell access to major sites of metastasis such as bone, lungs, and lymph nodes, optimizing antigen presentation, and inducing a persistent immune response. This paper reviews the cutting-edge trends in nano-immunoengineering for metastatic cancers with an emphasis on different nano-immunotherapeutic strategies. Specifically, it discusses directly reversing the immunological status of the primary tumor, harnessing the potential of peripheral immune cells, preventing the formation of a pre-metastatic niche, and inhibiting the tumor recurrence through postoperative immunotherapy. Finally, we describe the challenges facing the integration of nanoscale immunomodulators and provide a forward-looking perspective on the innovative nanotechnology-based tools that may ultimately prove effective at eradicating metastatic diseases.

show abstract

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

Cited by 28 publications

References 62 publications

AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties

AIM Platform: A Novel Nano Artificial Antigen-Presenting Cell-Based Clinical System Designed to Consistently Produce Multi-Antigen-Specific T-Cell Products with Potent and Durable Anti-Tumor Properties

Emerging vaccine nanotechnology: From defense against infection to sniping cancer

Nanotechnology-enhanced immunotherapy for metastatic cancer

Contact Info

Product

Resources

About